{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006972","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.716060+00:00","generated_at":"2026-06-18T08:17:44.599416+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ChromaDex Q4 revenue $21.0M (+18% YoY), Adj EBITDA turns positive at $0.4M","bullets":["Q4 net sales $21.0M (+18% YoY); Tru Niagen sales $16.1M (+14% YoY).","Net loss narrowed to $1.4M ($0.02 loss per share) from $5.3M loss a year ago.","Adjusted EBITDA profit $0.4M, a $3.8M improvement vs Q4 2021 loss.","Full year net sales $72.0M (+7%); net loss $16.5M, improved $6.6M YoY.","Signed long-term supply deal with Nestlé Health Science; entered China via Sinopharm Xingsha."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006972","json":"https://secwatch.observer/filing/0001628280-23-006972.json","markdown":"https://secwatch.observer/filing/0001628280-23-006972.md","text":"https://secwatch.observer/filing/0001628280-23-006972.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/0001628280-23-006972-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/cdxc-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:17:44.599416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a58b378dfda261bb27ab0a0366cb35133a10c78","claim":"Niagen Bioscience, Inc. reported financial results for fourth quarter and the year ended December 31, 2022.","evidence_excerpt":"On March 8, 2023, ChromaDex Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023006972/0001628280-23-006972-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}